在患有恶性贫血的患者中,与高血糖血症相关的血栓形成
Thura W Htut1, Kyaw Z Thein2, Thein H Oo3
1Department of Haematology, Aberdeen Royal Infirmary, University of Aberdeen, NHS Grampian, Aberdeen, UK.
Journal of community hospital internal medicine perspectives
|January 27, 2025
概括
恶性贫血 (PA) 可以导致高血糖蛋白质血症相关的血栓形成症 (HAT),经常出现在异常部位,带有神经精神疾病症状. 用可巴拉明替代剂和抗血栓剂治疗显示,复发性血栓形成的发生率较低.
科学领域:
- 血液学 血液学 血液学
- 胃肠病学 胃肠病学
- 神经学 神经学
背景情况:
- 由于恶性贫血 (PA) 导致的巴胺缺乏症 (CD) 会导致高血糖血症,这是已知的血栓形成的危险因素.
- 与PA相关的高homocysteinemia相关血栓塞 (HAT) 的临床特征和结果仍然不太清楚.
研究的目的:
- 阐明患有二次性至恶性贫血 (PA) 的高homocysteinemia相关血栓症 (HAT) 的患者的临床特征和结果.
主要方法:
- 在PubMed,Scopus和Web of Science数据库中进行了全面的文献搜索,截至2024年1月.
- 关键词包括"恶性贫血和血栓症"和相关术语,以确定相关的发表研究.
- 审查的重点是提取临床数据来表征PA相关的HAT.
主要成果:
- 该研究分析了20名患者,平均年龄为54.5岁;35%是老年人.
- 重要发现包括多个或异常部位的血栓 (分别为35%和20%) 和同时存在的神经精神症状 (45%).
- 80%的测试结果对抗内在因子 (anti-IF) 抗体呈阳性,并且在治疗后没有观察到复发性血栓栓塞.
结论:
- 与恶性贫血相关的高homocysteinemia相关的血栓形成是一种罕见的疾病,其特点是异常/多重血栓形成的高发病率和相关的神经精神症状.
- 发现抗内在因子抗体阳性的高率.
- 科巴胺替代药物和抗血栓治疗在预防复发性血栓栓塞事件方面显得有效.
相关概念视频
Disorders of Hemostasis
690
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
690
Anticoagulant Drugs: Low-Molecular-Weight Heparins
602
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
602
Peptic Ulcer Disease I: Introduction
126
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
126
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
53
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
53
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
349
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
349
Gastritis III: Clinical Manifestations and Management
135
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
135


